Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer
Authors:
- Vivany Maydel Sierra-SánchezVSVivany Maydel Sierra-Sánchez
- Sergio Adrian Ocampo-OrtegaSOSergio Adrian Ocampo-Ortega
- Santiago Villafaña-HernandezSVSantiago Villafaña-Hernandez
- Elvia Mera JiménezEJElvia Mera Jiménez
- Rolando Alberto Rodríguez FonsecaRolando Alberto Rodríguez Fonseca
- Asdrubal Aguilera-MéndezAAAsdrubal Aguilera-Méndez
- Rodrigo Romero-NavaRRRodrigo Romero-Nava
- Enrique HongEHEnrique Hong
- Martha Edith Macías-PérezMMMartha Edith Macías-Pérez
- Santiago VillafañaSVSantiago Villafaña
Open Access
- 30 June 2026
- journal article
- research article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 53
Abstract
In triple-negative breast cancer (TNBC), immune checkpoint pathways play a central role in tumor immune evasion. Programmed death protein 1 (PD-1) is an inhibitory receptor expressed on T cells, while its ligand, programmed death-ligand 1 (PD-L1), is commonly expressed on tumor cells and cells within the tumor microenvironment. Their interaction suppresses T-cell activation and promotes immune escape. In this study, we evaluated the potential of small interfering RNA (siRNA) to silence PD-L1 expression in TNBC. Transcriptomic analysis of GEO datasets revealed consistent upregulation of CD274 (PD-L1) in TNBC samples. Three siRNA candidates were designed and evaluated in MDA-MB-231 cells. All siRNAs significantly reduced CD274 expression (>70%), as determined by RT-qPCR. Immunofluorescence analysis confirmed a reduction in PD-L1 protein levels (54.3 vs. 98.7 a.u.), while MTT assays demonstrated preserved cell viability at the working concentration (100 pM), supporting a non-cytotoxic and specific gene-silencing effect. These findings highlight PD-L1 as a viable molecular target and support siRNA-mediated silencing as a promising therapeutic strategy in TNBC.Keywords
Funding Information
- Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional (IND-2026-0043)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (CVU: 1101281)
This publication has 34 references indexed in Scilit:
- APEX3 – An Optimized Tool for Rapid and Unbiased Proximity LabelingJournal of Molecular Biology, 2023
- Regulation of programmed death ligand 1 (PD‐L1) expression by TNF‐related apoptosis‐inducing ligand (TRAIL) in triple‐negative breast cancer cellsMolecular Carcinogenesis, 2022
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerAnnals of Oncology, 2021
- A review of the tortuous path of nonviral gene delivery and recent progressInternational Journal of Biological Macromolecules, 2021
- PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokinesBiomedicine & Pharmacotherapy, 2021
- Mechanisms Controlling PD-L1 Expression in CancerMolecular Cell, 2019
- A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionCancer Immunology, Immunotherapy, 2018
- Three-dimensional culture systems in cancer research: Focus on tumor spheroid modelPharmacology & Therapeutics, 2016
- 13C NMR Relaxation Studies of RNA Base and Ribose Nuclei Reveal a Complex Pattern of Motions in the RNA Binding Site for Human U1A ProteinJournal of Molecular Biology, 2005
- Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophagesBiochemical and Biophysical Research Communications, 2004